GensKey

As a leading enterprise in the field of high-throughput genetic testing for infectious pathogens, GensKey has established medical laboratories in Beijing, Shanghai, Tianjin, Guangzhou, and Wuhan. Currently, GensKey has become the infectious disease genetic testing company with the largest number of medical laboratories across China and the fastest turnaround time. Meanwhile, GensKey is actively promoting the adoption of its “Jinshiyuan” pathogen metagenomic testing project in hospitals, providing comprehensive solutions for infectious disease genetic testing to large Grade A tertiary hospitals in more than ten cities, including Shenzhen, Chengdu, Zhengzhou, Xi’an, and Nanchang. By collaborating with healthcare institutions to achieve localized delivery, GensKey has enhanced these hospitals’ capabilities in disease diagnosis and nosocomial infection monitoring.GensKey places significant emphasis on integrating product research and development with clinical practice. It has established in-depth collaborations with top-tier medical institutions, including China-Japan Friendship Hospital, Peking University People’s Hospital, West China Hospital of Sichuan University, the Hematology Hospital of the Institute of Hematology at the Chinese Academy of Medical Sciences, and Lu Daopei Medical Group. Conducting multi-center clinical studies across disciplines such as respiratory medicine, hematology, and infectious diseases, GensKey has deeply customized experimental workflows and algorithms for pathogen metagenomics, launching differentiated pathogen genetic testing products to improve detection sensitivity and specificity. Additionally, leveraging nanopore third-generation sequencing technology, GensKey has launched molecular diagnostic products for rapid testing and antimicrobial resistance detection, committed to precisely addressing challenges in clinical infection management and quality control in the pharmaceutical and biological products sectors.